دورية أكاديمية
Survival and prognostic factors among hospitalized pancreatic cancer patients in northwestern Iran.
| العنوان: | Survival and prognostic factors among hospitalized pancreatic cancer patients in northwestern Iran. |
|---|---|
| المؤلفون: | Vahedi L; Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Asvadi Kermani T; General and Vascular Surgery_trauma Fellowship, Tabriz University of Medical Sciences, Tabriz, Iran., Asghari-Jafarabadi M; Cabrini Research, Cabrini Health, Melbourne, VIC, 3144, Australia.; School of Public Health and Preventative Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, 3800, Australia., Asghari E; Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Mohammadi SM; Department of Anatomical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran., Khameneh A; Student Research Committee, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. |
| المصدر: | Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences [J Res Med Sci] 2023 Jan 31; Vol. 28, pp. 4. Date of Electronic Publication: 2023 Jan 31 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Medknow Publications and Media Pvt. Ltd Country of Publication: India NLM ID: 101235599 Publication Model: eCollection Cited Medium: Print ISSN: 1735-1995 (Print) Linking ISSN: 17351995 NLM ISO Abbreviation: J Res Med Sci Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Mumbai : Medknow Publications and Media Pvt. Ltd. Original Publication: Isfahan, Iran : Isfahan University of Medical Sciences |
| مستخلص: | Background: Pancreatic cancer (PC) is associated with a poor prognosis, with various modifiable risk factors affecting the survival of patients. Our aim was to evaluate the survival rate and the prognostic factors influencing survival in PC patients in northwestern Iran. Materials and Methods: All the PC patients admitted to the Imam Reza Hospital of Tabriz, Iran, from 2016 to 2020, were enrolled in this study. The survival rate and time were calculated, and the risk factors related to survival were evaluated by Cox regressions. The data were analyzed using the Cox proportional hazards model using STATA software. Results: Of 110 patients, 12-, 24-, 36-, and 48-month survival rates were 29.1%, 19.8%, 14.1%, and 8.5%, respectively, with the median survival time of seven months. The mean age was 65.5 years. The results showed that a higher age (hazard ratio [HR] [95% confidence interval (CI)] = 2.04 [1.20-3.46]), lower education (1.72 [1.03-2.89]), delayed diagnosis (1.03 [1.02-1.05]), hypertension (1.53 [1.01-2.31]), concomitant heart disorders (2.67 [1.50-4.74]), COPD (4.23 [1.01-17.69]), consanguineous marriage (1.59 [1.01-2.50]), and the presence of icterus complications (adjusted HR = 3.64 [1.56-8.49]) were directly associated with a worse survival. On the contrary, radiotherapy (0.10 [0.01-0.85]), chemotherapy (0.57 [0.36-0.89]), and surgical therapy (AHR = 0.48 [0.23-0.99]) were directly related to a good prognosis. Conclusion: Surgery, chemotherapy, and radiotherapy were the best predictors of survival in PC patients. Moreover, it seems that resolving jaundice can improve survival in these patients. It seems that increasing social awareness, treating underlying diseases, and employing an appropriate therapeutic method may promise a better outlook, improve the survival rate of patients, and reduce PC risk. Competing Interests: There are no conflicts of interest. (Copyright: © 2023 Journal of Research in Medical Sciences.) |
| References: | World J Oncol. 2019 Feb;10(1):10-27. (PMID: 30834048) Cancer Med. 2018 Jun;7(6):2328-2338. (PMID: 29665327) Cancers (Basel). 2018 Feb 11;10(2):. (PMID: 29439461) Br J Surg. 2004 Nov;91(11):1410-27. (PMID: 15499648) Acta Oncol. 2019 Jun;58(6):864-871. (PMID: 30905248) Int J Cancer. 2010 Nov 15;127(10):2412-9. (PMID: 20143395) Br J Cancer. 2014 Jul 8;111(1):181-5. (PMID: 24786605) Sci Rep. 2020 Apr 27;10(1):7048. (PMID: 32341400) Sci Rep. 2020 Oct 2;10(1):16425. (PMID: 33009477) Cancer. 2005 Jan 15;103(2):349-57. (PMID: 15593353) JAMA Surg. 2016 Apr;151(4):338-45. (PMID: 26581025) Lancet. 2004 Mar 27;363(9414):1049-57. (PMID: 15051286) J Gastrointest Cancer. 2017 Mar;48(1):58-65. (PMID: 28025817) Am J Epidemiol. 2011 Dec 15;174(12):1373-81. (PMID: 22047824) Iran Red Crescent Med J. 2016 Jan 06;18(4):e29615. (PMID: 27275400) Clin Gastroenterol Hepatol. 2021 May;19(5):876-884. (PMID: 32147593) Cancer Med. 2017 Oct;6(10):2278-2286. (PMID: 28925039) Am J Surg. 2006 Sep;192(3):322-9. (PMID: 16920426) JAMA Oncol. 2015 Apr;1(1):88-96. (PMID: 26182310) Cancer Causes Control. 2018 Nov;29(11):1059-1069. (PMID: 30194549) J Res Med Sci. 2020 Dec 30;25:114. (PMID: 33912224) Pancreas. 2014 Jan;43(1):47-52. (PMID: 24177141) Oncotarget. 2020 Mar 10;11(10):924-941. (PMID: 32206189) Cancer. 1978 Nov;42(5):2494-506. (PMID: 363259) Ann Surg Oncol. 2013 Dec;20 Suppl 3:S443-9. (PMID: 23128941) Cancer. 2017 Oct 1;123(19):3816-3824. (PMID: 28621885) |
| فهرسة مساهمة: | Keywords: Pancreatic cancer; prognosis; survival |
| تواريخ الأحداث: | Date Created: 20230328 Latest Revision: 20230329 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC10039100 |
| DOI: | 10.4103/jrms.jrms_54_21 |
| PMID: | 36974115 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1735-1995 |
|---|---|
| DOI: | 10.4103/jrms.jrms_54_21 |